“Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States,” said Surgeon General Vivek Murthy, MD.
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
Despite the increasing number of women in medicine, gender disparities in leadership and career advancement, particularly in oncology, remain prominent. Addressing issues such as pay…
A stem cell donor changed Laura Tiberi’s life after her leukemia diagnosis. Now she’s sharing hope and inspiration with other transplant recipients.
An abstract is unavailable.
